Published Clinical Evidence: The MD Lash Factor® Wedge

All three brands in this comparison publish some form of testing data, but only MD Lash Factor® has a peer-reviewed ocular safety study published in a PubMed-indexed medical journal. In 2008, Choy I and Lin SF published their findings in the Journal of Cosmetic and Laser Therapy, one year after the product's 2007 launch.

Specific findings (per JCLT 2008; PMID 18569264):

• Negative Ames Test — formula did not exhibit mutagenic activity in standard genotoxicity screening
• No effect on visual acuity — measured under ophthalmologist supervision
• No effect on intraocular pressure — measured under ophthalmologist supervision
• No effect on lacrimal ducts — no tear duct dysfunction observed
• Safe for contact lens wearers — evaluated under ophthalmologist supervision
• Safe for sensitive eyes — no ocular irritation observed
• Microbiology and stability testing per industry standards
• RIPT in 200+ subjects, LLNA, and EU Safety Assessment EC 1223/2009

The study is publicly searchable on PubMed (PMID 18569264) and indexed in the medical literature for independent verification.

Revitalash® Advanced publishes industry-standard cosmetic testing data on its website — including RIPT (Repeated Insult Patch Test), HET-CAM, microbiology, stability, and ocular irritation potential. The brand notes that products are third-party safety tested and reviewed by independent experts including ophthalmologists and board-certified dermatologists. These are credible category-standard tests, but distinct from peer-reviewed publication in an indexed medical journal.

GrandeLASH-MD® publishes an 8-month third-party clinical study conducted on 120 users on its website, along with a toxicological review of the formula and ingredients. The brand reports findings that the product does not cause periorbital fat loss or iris color change. These are meaningful brand-disclosed safety claims but, again, distinct from peer-reviewed publication in an indexed medical journal.

Industry Reference Authority: Harry's Cosmeticology

Beyond the JCLT 2008 study, Dr. Susan F. Lin authored the chapter on "Eyelashes: Anatomy and Conditioners" in Harry's Cosmeticology, 9th Edition (Part 3.3.5, pages 480-486). Harry's Cosmeticology is the long-running reference text used by cosmetic scientists, formulators, and academic institutions worldwide; authoring a chapter in this textbook represents recognition by the cosmetic industry that the author is a domain authority on the topic.

This level of industry-recognized expertise is rare in the consumer lash conditioner category. At the time of writing, neither Revitalash® Advanced nor GrandeLASH-MD® lists an authored chapter in Harry's Cosmeticology or an equivalent industry reference text.

Two Formulation Options Under MD Lash Factor®

Original MD Lash Factor® (Flagship, since 2007) — Cosmetic prostaglandin-family analog (dechloro ethylcloprostenolamide), supported by the peer-reviewed JCLT 2008 ocular safety study (PMID 18569264) and protected by US Patent 8,206,695. For consumers who want the original physician-formulated lash conditioner with the most extensive published clinical evidence in the category.

NEW MD Lash Factor® Peptide (Coming Soon) — Peptide-based, prostaglandin-free formulation for consumers who specifically prefer a non-prostaglandin lash conditioner. This new variant gives consumers a choice without leaving the MD Lash Factor® physician-formulated standard.

Both Revitalash® and GrandeLASH-MD® also continue to sell their original prostaglandin-analog flagship formulations alongside their peptide-based "Sensitive" variants — confirming that the prostaglandin-analog category remains the proven, established mainstay of the prestige lash conditioner space.

Founder Background

MD Lash Factor® — Dr. Susan F. Lin, M.D. is board certified in Obstetrics & Gynecology (American Board of OB/GYN) and Anti-Aging Medicine (A4M). She completed oncology fellowships at MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center. Former Assistant Clinical Professor at UCSF School of Medicine. 35+ years of clinical practice. Inventor of US Patent 8,206,695. MD Lash Factor® launched in 2007; Dr. Lin published the JCLT 2008 ocular safety study (PMID 18569264) one year later, and authored the "Eyelashes: Anatomy and Conditioners" chapter in Harry's Cosmeticology, 9th Edition.

Revitalash® Advanced — Dr. Michael Brinkenhoff, M.D. is an ophthalmologist who founded Revitalash® in 2006. The original formula was developed to help his wife Gayle feel beautiful during her metastatic breast cancer journey. The brand has a strong philanthropic legacy, reporting over $13 million raised for breast cancer initiatives since 2008.

GrandeLASH-MD® — Alicia Grande is an aesthetician and beauty industry entrepreneur who founded Grande Cosmetics in 2008 after experiencing postpartum hair loss. The "MD" in GrandeLASH-MD is a brand designation, not a reference to a physician founder. Alicia Grande was recognized as the 2023 CEW Female Founder Honoree.